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DOI 10.1016/j.ccr.2009.12.050SUMMARYThe BCL6 transcriptional repressor is the most frequently involved oncogene in diffuse large B cell lymphoma
(DLBCL). We combined computer-aided drug design with functional assays to identify low-molecular-weight
compounds that bind to the corepressor binding groove of the BCL6 BTB domain. One such compound dis-
rupted BCL6/corepressor complexes in vitro and in vivo, and was observed by X-ray crystallography and
NMR to bind the critical site within the BTB groove. This compound could induce expression of BCL6 target
genes and kill BCL6-positive DLBCL cell lines. In xenotransplantation experiments, the compound was
nontoxic and potently suppressed DLBCL tumors in vivo. The compound also killed primary DLBCLs from
human patients.INTRODUCTION
BCL6 is the most frequently involved oncogene in diffuse large B
cell lymphomas (DLBCLs) (Ye, 2000). In normal lymphoid biology
BCL6 is required for mature B cells to form germinal centers
(GCs), which are cellular compartments dedicated to the affinity
maturation of antibodies (Dent et al., 1997; Ye et al., 1997). In
order to generate clonal diversity of cells expressing the greatest
possible variations in their immunoglobulin coding sequence, B
cells must acquire the ability to simultaneously tolerate rapid
proliferation and genomic recombination. BCL6 facilitates this
phenotype of physiological genomic instability by repressing
genes involved in sensing DNA damage or their downstream
checkpoints (Phan and Dalla-Favera, 2004; Phan et al., 2005;Significance
BCL6 is the most commonly involved oncogene in B cell lymp
cells and BCL6 is thus a critical therapeutic target. Like many o
factor. Because such proteins usually mediate their actions thr
considered nonamenable to targeting with small molecules. He
approach to identify an effective and specific BCL6 small-mo
netics, pharmacodynamics, toxicity, and therapeutic efficac
repressors can be therapeutically targeted with small molecu
approach for the treatment of lymphomas.
400 Cancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc.Ranuncolo et al., 2007; Ranuncolo et al., 2008). Mice engineered
to constitutively express BCL6 in GC B cells develop DLBCL
similar to the human disease (Baron et al., 2004; Cattoretti
et al., 2005). BCL6 is also expressed constitutively in themajority
of patients with aggressive B cell lymphomas, most often due to
translocations of heterologous promoter elements or promoter
point mutations in the BCL6 locus (Ye, 2000). BCL6 loss of func-
tion, mediated by delivery of shRNA or peptide inhibitors, can kill
DLBCL cells, demonstrating that BCL6 is required for survival of
lymphoma cells and could be an excellent therapeutic target
(Cerchietti et al., 2008; Cerchietti et al., 2009; Phan and Dalla-
Favera, 2004; Polo et al., 2004; Polo et al., 2007).
BCL6 is a member of the BTB/POZ family of transcription
factors (Stogios et al., 2005). The BCL6 BTB domain has potenthomas. Depletion or blockade of BCL6 potently kills DLBCL
ncogenes and tumors suppressors, BCL6 is a transcription
ough extensive protein interaction surfaces, they have been
rein, we used an integrated biochemical and computational
lecule inhibitor. This drug displayed favorable pharmacoki-
y. This work demonstrates that oncogenic transcriptional
les and presents a rationally designed transcription therapy
Figure 1. The Structure of the BCL6 BTB Domain
(A) Structure of the 2:2 complex between the BCL6 BTB domain and the SMRT
BBD peptide. The two chains of the BTB domain are shown in pink and blue
and the two SMRT peptides are shown in stick representation with green
carbon atoms. The SMRT 1423-1428 region is circled.
(B) View of the selected compounds docked to the BCL6 lateral groove pocket
predicted by the CADD procedure along with the putative binding site repre-
sented by green transparent spheres. The compounds are stick representa-
tions based on the following color scheme: 28 (blue), 72 (magenta), 79 (red),
53 (yellow), and 55 (green). See also Figure S1 and Table S1.
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BCL6 Small-Molecule Inhibitorsautonomous repressor activity, which is dependent on its ability
to recruit the SMRT, N-CoR, and BCOR corepressors to an
exposed surface groove formed at the interface of the two chains
in the BTB dimer (Ahmad et al., 2003; Ghetu et al., 2008). These
corepressors interact with micromolar affinity to the lateral
groove of the BCL6 BTB domain via a 17-residue BCL6 binding
domain (BBD) (Ahmad et al., 2003; Ghetu et al., 2008). The resi-
dues that define the BCL6 lateral groove surface are not
conserved in other transcription factors from the BTB family
(Ahmad et al., 2003; Ghetu et al., 2008; Stogios et al., 2007).
Notably, a cell-penetrating BCL6 peptide inhibitor (BPI) contain-
ing the SMRT BBD inhibits the transcriptional repressor activity
of BCL6 but has no effect on other BTB repressors (Polo et al.,
2004). Moreover, BPI induces the upregulation of critical BCL6
target genes including atr, chek1, and tp53 in DLBCL cell lines
(Cerchietti et al., 2008; Cerchietti et al., 2009; Ranuncolo et al.,
2007; Ranuncolo et al., 2008).
Our goal was to use structure-based strategies to identify
small molecules that specifically disrupt the activity of BCL6
by blocking its interaction with its corepressors BCOR, N-CoR,
and SMRT. In addition, we wanted to determine whether these
compounds would reactivate BCL6 target genes and selectively
kill BCL6-dependent lymphoma cells in vitro and in vivo.
RESULTS
Computer-Aided Drug Design Identifies
Low-Molecular-Weight Compounds with
the Potential to Bind to the BCL6 Lateral Groove
Structural analyses of the BCL6-BBD complex (Ahmad et al.,
2003; Ghetu et al., 2008) indicated that the region of the lateral
groove associated with SMRT residues 1423-1428 had a high
complexity and density of intermolecular contacts between the
protein and BBD peptide (Figure 1A). Alanine scanningmutagen-
esis confirmed that all six of these BBD residues are required for
the stability of the complex (Ghetu et al., 2008). Therefore, this
region was selected for the application of computer-aided drug
design (CADD) to identify low-molecular-weight compounds
with the potential to bind in the BCL6 lateral groove. The first
step of CADD involved identification of putative small-molecule
binding sites with the SPHGEN module in the program DOCK
(Kuntz, 1992). The resulting sphere set was used to direct
a CADD screen of a database of over 1,000,000 commercially
available compounds. Screening involved two rounds of docking
of the compounds into the putative binding site with final
compound selection based on maximizing both chemical diver-
sity (Butina, 1999) and physical properties associated with drug-
like characteristics (Lipinski, 2000). In the first round of CADD,
50,000 compounds having the most favorable N-normalized
van der Waals (vdW) attractive energy were selected. This
normalization procedure (Pan et al., 2003) centers the median
of molecular weight (MW) distribution of selected compounds
to approximately 300 daltons, consistent with the known MW
distribution of drug-like molecules (see Figure S1A available
online) (Lipinski, 2000). In addition, the use of the vdW attractive
energy for ranking eliminates compounds that do not sterically
complement the putative binding pocket (Huang et al., 2004).
In the second round of docking, additional conformations of
the protein were included to partially account for the conforma-tional flexibility of the binding pocket. These additional con-
formations were obtained from amolecular dynamics (MD) simu-
lation of the apo (unliganded) BCL6 BTB domain. Included in
Table S1 are root-mean-square deviation (rmsd) values of resi-
dues in the binding region for the different conformations. This
more rigorous second-step screening yielded a final ranking
of 1000 compounds as evaluated with the N2/5-normalized total
interaction energy (selected from the initial 50,000 compounds)
(Figure S1B). The 1000 compounds were then subjected to
chemical diversity clustering which yielded approximately 100
groups, consisting of compounds with related chemical struc-
tures. One or two compounds were then selected from each
group based on maximizing adherence to Lipinski’s Rule of
Five (Lipinski, 2000), yielding a total of 199 compounds. The
CADD-identified inhibitors were predicted to bind in the vicinity
of the targeted binding site, assuming a variety of orientations
within the BCL6 lateral groove. A total of 100 of the final 199
compounds were available from commercial vendors for exper-
imental testing. The Figure 1B shows the CADD-selected
compounds docked to the BCL6 lateral groove pocket along
with the green transparent spheres used to define the putative
binding site.
Compounds Identified by CADD Can Inhibit BCL6 BTB
Domain Repressor Activity
To determine whether compounds selected by CADD could
inhibit the repressor activity of the BCL6 BTB domain, we per-
formed reporter assays in which a GAL4 DNA binding domain
(DBD)-BCL6BTB fusion construct was cotransfected with a lucif-
erase reporter plasmid containing GAL4 DBD binding sites,
(GAL4)5TK-Luc. The fold change in repressor activity of the
BCL6 BTB domain was determined in the presence of either
the CADD-selected compounds at a 50 mM concentration or
vehicle, and was controlled for nonspecific effects on transcrip-
tion by normalizing to the activity of the GAL4-DBD alone. Ten
compounds consistently attenuated BCL6BTB-mediated tran-
scriptional repression compared with vehicle control (dimethyl
sulfoxide [DMSO]) (Figure 2A) and were thus candidate inhibitors
of corepressor binding to the BCL6 lateral groove. StructuresCancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc. 401
Figure 2. CADD Selection Identifies BCL6
Inhibitor Compounds
(A) Reporter assays were performed to test the
impact of CADD compounds on the repressor
activity of a GAL4-DBD-BCL6BTB fusion construct,
compared with their effect on GAL4-DBD alone.
The y axis shows the relative percent of repression
mediated by GAL-BCL6BTB in the presence of
vehicle (V, which is set as 100%), compounds
with activity (black bars and 79 as red bar) or
selected inactive compounds (gray bars). Com-
pounds were tested at 50 mM in DMSO. Experi-
ments were performed in triplicate with com-
pounds tested in quadruplicate.
(B) Reporter assay as in (A) was performed with
families of compounds related to those in (A).
The x axis lists the compounds according to which
parental compound they are similar to. The 79
series is shown in black and 79-6 is shown in red.
Compoundswere tested at 100 mM in DMSO. Error
bars represent thestandarderrorof themean (SEM)
for replicates. See also Figure S2 and Table S2.
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Figure S2A and Table S2. Compounds structurally similar to
the active compounds were identified based on the Tanimoto
Similarity Index (Butina, 1999) and subjected to biological
testing, with the exception of compound 46 analogs, which
were not available. In BCL6 BTB reporter assays, several of
the similar compounds retained the activity of the parental mole-
cule, with the most potent derivatives belonging to the series 28
and series 79 families (Figure 2B). In addition, active analogs
were also present for families 72, 53, and 55, suggesting that
these compounds may also be suitable for further investigation.
The 79 series compounds were selected for further study
because this group contained the largest number of active
compounds, with 11 of 13 compounds attenuating transcrip-
tional repression by greater than 50%. One of the 79-series
compounds (79-40) with the smallest effect on transcriptional
derepression was selected to use as a chemical control for
selected subsequent experiments (Figure S2B).
79-6 Binds to a Pocket in the Lateral Groove of the BCL6
BTB Domain
Compound 79-6 was synthesized and purified from commercial
sources. The purity and identity of compound 79-6 were verified
by 1H nuclear magnetic resonance (NMR), elemental analysis,
and liquid chromatography mass spectrometry (LC/MS) (Fig-
ure S3). We used X-ray crystallography to determine the binding
location of 79-6 on the BCL6BTB domain. Crystals of BCL6BTB
were soaked with 79-6 and we observed that the crystals
changed to the orange color that is characteristic of the 79 series
(Figure 3A). A 2.3 A˚ diffraction data set was collected on the
soaked crystals, and after several rounds of refinement, differ-402 Cancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc.ence density jFo – Fcj maps were used
to locate the positions of 79-6. Crystallo-
graphic statistics are provided in Table
S3. The strong positive peak for the
79-6 bromine atom was used to anchor
the molecule, but the density was not asstrong at the more exposed end of the molecule (Figure 3B).
As anticipated based on previous functional assays, two mole-
cules of 79-6 bind at equivalent positions in the lateral grooves
on either side of the BCL6 BTB dimer. The indolazine ring of
79-6 is positioned within a shallow preformed pocket near
Tyr-58 that is empty in the apo structure of BCL6 BTB, and is
occupied by SMRT residues His-1426/Ile-1428, or BCOR Trp-
509/Val-511 in the two BBD corepressor structures (Ghetu
et al., 2008). Thus, the presence of 79-6 in the binding pocket
would prevent the interaction of BCL6 with BBD-corepressor
residues that are essential for complex formation. The 79-6 indo-
lazine ring is sandwiched between Tyr-58 from one BCL6 chain
and Asn-21 and Arg-24 from the other chain (Figures 3C and 3D).
Leu-25 lines a hydrophobic pocket that accepts the bromine
from the 79-6 indolazine ring, while the main-chain carbonyl
oxygen of Met-51 and the guanidinium group of Arg-28 form
polar interactions with the compound. The indolazine ring
anchors the molecule in the lateral groove pocket of the protein,
and the electron density becomes progressively weaker toward
the carboxylic acid tail. The strength of the electron density
correlates with the degree of burial of the compound from the
fused ring system to the tail. Nevertheless, MD simulations
have indicated the presence of interactions between the carbox-
ylic acid groups and the guanidinium groups of Arg 24 and
Arg 28, but these were very highly dynamic which is consistent
with the weak electron density in this region (results not shown).
NMR spectroscopy was used for characterizing the binding
of 79-6 to the BCL6 BTB domain in solution. BCL6BTB gave
a well-dispersed 15N heteronuclear single quantum coherence
(HSQC) spectrum, and assignments were obtained for 82 of
the 121 observed main-chain resonances with triple-resonance
Figure 3. Crystallography of the BCL6BTB/
79-6 Complex
(A) The crystal on the right was soaked with
compound 79-6 prior to transferring it to a well
with no added compound. The crystal on the left
was not soaked in 79-6.
(B) jFo-Fcj difference electron density contoured
at 4 s (red mesh) and 2 s (gray mesh) in the lateral
groove site of the BCL6BTB dimer prior to the inclu-
sion of the compound in the model. The stick
model represents the final refined position of
79-6. The bromine atom of the compound is
located in the region of highest electron density.
(C) Compound 79-6 is shown in a space filling
representation with green carbon atoms, and
binds in the lateral groove of the BTB dimer.
(D) Details of the molecular interactions between
79-6 and the BCL6 BTB domain. The bromine
atom of the indolazine ring of 79-6 is colored
brown. Residues Asn-21, Arg-24, Leu-25 and
Arg-28 are from one chain, and residues labeled
with primes (Gly-550, Tyr-580 and Ser-590) are
from the other BCL6 chain. See also Figure S3
and Table S3.
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increasing concentrations of 79-6, and we observed the selec-
tive shifting of a subset of resonances that cluster near the lateral
groove pocket (Figure 4 and Figure S4). To further confirm that
79-6 interacts with the lateral groove of the BTB domain, NMR
HSQC measurements were performed on BCL6BTB in the pres-
ence of a 2-fold molar excess of unlabelled SMRT BBD peptide
(Figure S4). Notably, resonances shifted by 79-6 were also
shifted by the SMRT BBD peptide indicating that 79-6 is binding
to the targeted region of the protein in solution (Figure S4). As
expected, the smaller 79-6 molecule affected only a subset of
the spectra shifted by the significantly larger BBD. The shifts of
five strongly affected resonances with increasing concentrations
of 79-6 were fit to a binding isotherm, resulting in a Kd of 138 ± 31
mM (Figure 5). We also measured the displacement of a fluores-
cently labeled SMRT-BBD peptide from the BCL6BTB core-
pressor complex by a fluorescence polarization competitive
binding assay. Under these assay conditions, compound 79-6
had an IC50 value of 212 mM, which corresponds to a Ki of
147 mM, whereas compound 79-40 had a Ki > 1 mM (Figure S5).
In addition, 79-6 has a ligand efficiency of 0.21, which is compa-
rable to other small-molecule inhibitors of protein-protein inter-
actions (Wells and McClendon, 2007).
79-6 Specifically Inhibits BCL6 but Not Other BTB-ZF
Proteins
Although the residues lining the lateral groove of BCL6 are not
conserved in other BTB domains, it was still possible that 79-6
may nonspecifically affect the transcriptional repression of other
BTB-containing proteins. To determine whether this was the
case we performed reporter assays that included other BTB-
zinc finger repressors in the same family as BCL6. GAL4-DBD
fusions of the BTB domains of BCL6, Kaiso, HIC1 (hypermethy-lated in cancer 1) and PLZF (promyelocytic zinc finger) were
examined for their ability to repress the (GAL4)5TK-Luc reporter
in the presence of 79-6 (Figure 6A). 79-6 readily attenuated
BCL6-mediated repression but had little or no effect on the other
BTB domains. These assays demonstrate that 79-6 mediates
specific de-repression of BCL6 transcriptional activity, but not
that of other BTB containing transcriptional repressors.
79-6 Disrupts BCL6 Transcriptional Complexes and
Reactivates BCL6 Target Genes
BCL6 mediated repression of the atr gene has been suggested
to contribute to lymphomagenic actions of BCL6 and is depen-
dent on the BCL6 lateral groove (Ranuncolo et al., 2007). To
determine whether the BCL6 repression complex on the atr
promoter could be disrupted by 79-6, we exposed a BCL6-posi-
tive DLBCL cell line (SU-DHL6) to 79-6 at 125 mM or vehicle for
2 hr and then performed chromatin immunoprecipitations for
BCL6, SMRT, and N-CoR, followed by real-time polymerase
chain reaction (PCR) with primers designed to amplify the
BCL6 binding site in the atr promoter. 79-6 had no effect on
BCL6, but could disrupt recruitment of N-CoR and SMRT (both
of which contain a nearly identical BBD) to the atr promoter
(Figure 6B). In accordance with this result, exposure of BCL6-
dependent DLBCL SU-DHL4 and SU-DHL6 cells to 79-6 at
50 mM for 8 hr resulted in an increase in the abundance of atr
transcripts as well as an increase in the mRNA level of other
BCL6 target genes tp53, cd69, cdkn1a (P21), and cd44, but
not the non-target genes hprt, pcna, and b2m (Figure 6C).
However, 79-6 had no effect on any of these genes in the
BCL6-independent Toledo DLBCL cell line (Figure 6C). The inac-
tive chemical control 79-40 did not relieve BCL6 mediated
repression nor reactivate its target genes (Figures S6A and
S6B). Together, these data show that 79-6 specifically disruptsCancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc. 403
Figure 4. Nuclear Magnetic Resonance
Spectroscopy of BCL6BTB with 79-6
(A and B) Selected regions of the 15N-1H HSQC
spectra of BCL6BTB with increasing amounts of
79-6. The red spectrum was obtained in the
absence of the compound. The arrows indicate
shifted resonances.
(C) Residues whose amide NMR resonances
shifted by 0.05-0.09 ppm are colored light pink,
0.10-0.14 ppm are colored medium red, and >
0.15 ppm are colored dark red. The surface of
the BCL6 BTB dimer is colored gray and white.
See also Figure S4.
Figure 5. Binding Curves for 79-6 to the BCL6BTB
Binding curves for five resonances that shifted (y axis, in ppm) upon the addi-
tion of increasing concentrations of 79-6 (x axis). The fitting resulted in a Kd of
138 ± 31 mM. See also Figure S5.
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BCL6 target genes in BCL6-dependent DLBCLs.
79-6 Selectively Kills BCL6-Dependent DLBCL Cells
DLBCL cells can be classified into BCL6-dependent and inde-
pendent subtypes (Cerchietti et al., 2009; Polo et al., 2007;
Ranuncolo et al., 2007). Based on these data we examined the
sensitivity of eight DLBCL cell lines (six BCL6-dependent: OCI-
Ly1, SU-DHL4, OCI-Ly10, Farage, SU-DHL6 and OCI-Ly7, and
two BCL6-independent cell lines: Toledo and OCI-Ly4) to 79-6
in vitro. The cell lines were exposed to several concentrations
of 79-6 (administered only once at time-0) and examined for
cell viability at 48 hr with a metabolic luminescent assay. 79-6
induced a dose-dependent reduction of viability specifically in
BCL6-dependent, but not in the BCL6-independent, DLBCL
cell lines (Figure 6D). In contrast, the control compound 79-40
did not specifically kill BCL6-dependent DLBCL cells (Fig-
ure S6C). The 79-6 growth inhibition 50% (GI50) values were
between two and three orders of magnitude lower in the
BCL6-dependent group compared with the BCL6-independent
group. To determine the intracellular concentrations of 79-6,
we exposed OCI-Ly7 to 0 (DMSO), 0.05, 0.1, and 0.2 mM of
79-6 for 30 min and measured the intracellular concentration
of the drug by HPLC-MS/MS. We found that the cellular
accumulation of 79-6 is between 17 and 20 times higher
than the administered concentration (Figure S6D). This high
intracellular-to-extracellular concentration ratio is in accordance
with other antineoplastic and antibiotic drugs (Kuh et al., 2000;
Langer et al., 2005; Lemaire et al., 2009; Meyer et al., 1993;
Stamler et al., 1994). Thus, in cells, 79-6 reaches levels well
above its Ki when administered at these concentrations, which
is consistent with its BCL6-dependent inhibitory effects.404 Cancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc.79-6 Is Nontoxic to Animals
In order to determine whether 79-6
could serve as the basis for a clinically
useful BCL6 inhibitor, we first examined
whether it induced toxic effects in mice.
Five C57BL/6 mice were exposed to
daily intraperitoneal (i.p.) administration
of increasing doses of 79-6 ranging
from 0.5 to 50 mg/kg in 10% DMSO or
vehicle (10% DMSO, n = 5) over the
course of 12 days to a cumulative dose
of 278 mg/kg (Figure S7A). In no caseswere any toxic effects noted, such as lethargy, weight loss,
failure to thrive, or any other indicator of sickness. No evidence
of tissue damage was detected by microscopic examination of
mouse organs (Figure S7B). To determine whether the maximal
administered dose of 50 mg/kg will be tolerable in a 10 day
schedule, we conducted an additional toxicity study in C57BL/
6 mice. Ten mice were exposed to daily intraperitoneal (i.p.)
administration of 50 mg/kg 79-6 in 10% DMSO or vehicle
(10% DMSO, n = 5) over the course of 10 days to a cumulative
dose of 500mg/kg (Figure S7A). Fivemicewere sacrificed imme-
diately after the 10 day course of 79-6 administration (together
with five control mice) and five mice were sacrificed after a
10 day washout period to assess delayed toxicity. No toxic
Figure 6. 79-6 Specifically Inhibits BCL6
Repressor Activity
(A) Reporter assay comparing the effect of
50 mM 79-6 on the repressor activity of GAL4-
BCL6BTB, GAL4-KaisoBTB, GAL4-HIC1BTB, or
GAL4-PLZFBTB, compared with GAL4-DBD alone.
The y axis shows fold repression in the presence of
vehicle (black bars) compared with 79-6 (gray
bars).
(B) Quantitative chromatin immunoprecipitation
was performed in SU-DHL6 DLBCL cells to detect
binding of BCL6, N-CoR, and SMRT to the atr
promoter in the presence of vehicle (black bars)
or 125 mM of 79-6 (gray bars). The y axis shows
fold difference in enrichment of atr in the various
conditions.
(C) mRNA abundance of the BCL6 target genes
ATR, TP53, CD69, p21, and CD44, and the
nontarget genes B2M, PCNA, and HPRT was
measured in SU-DLH6, SU-DHL4 (both BCL6
dependent) and Toledo (BCL6 independent)
DLBCL cell lines exposed to vehicle or 50 mM
79-6 for 8 hr. The y axis shows 79-6 mediated
fold induction of each gene normalized to
RPL13A and relative to vehicle (DMSO).
(D) Dose-effect curves for a panel of eight DLBCL
cell lines exposed to increasing concentrations
of 79-6 for 48 hr. OCI-Ly7, OCI-Ly1, SU-DHL6,
SU-DHL4, OCI-Ly10, and Farage are BCL6-
dependent, and Toledo and OCI-Ly4 are BCL6-
independent negative controls. Cell viability was
determined by luminescent ATP quantization.
The value between parentheses represent the
drug concentration (in mM) that inhibits the
growth of cell lines by 50% compared with vehicle
(GI50). Assays were performed in biological tripli-
cates, with the averages of these plotted. Error
bars represent the SEM for replicates. See also
Figure S6.
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other indicator of sickness or tissue damage (macroscopic
or microscopic), were noted with either treatment schedule
(Figure S7C). Complete blood counts showed mild leucopenia
in all treated mice, although bone marrow (biopsy and smear)
was unaffected. Platelet and erythrocyte numbers were unaf-
fected. All mice completely recovered after the 10-day wash-
out period with no changes in plasma biochemistry values
(Table S4).
79-6 Displays Favorable Pharmacokinetics
In order to test whether 79-6 could perform as an antilymphoma
therapeutic agent in vivo, we determined whether it could pene-
trate tumors after parenteral administration through a distal site.
For this purpose 107 OCI-Ly7 cells were injected into the right
flank of ten severe combined immunodeficiency (SCID) mice
and allowed to form tumors. Once tumors reached 1.5 g,
animals were injected i.p. with a single dose of 50 mg/kg 79-6
in 10% DMSO or vehicle (10% DMSO) and sacrificed at 0.5, 1,1.5, 3, 6, 12, and 24 hr after the compound administration. Blood
and tumors were harvested. Quantitative HPLC/MS analysis of
the serum showed that 79-6 levels peaked (to 55 mg/ml, which
is equivalent to a 122 mM concentration) 1 hr after the i.p. injec-
tion (Figure 7A). 79-6 also reached its highest peak (24.5 ng/mg)
at the 1 hr time point in the tumors (Figure 7A), and after a sharp
decline in levels, decreased gradually over 24 hr. Therefore,
79-6 was able to reach tumors and persist within tumor tissue
after i.p. administration.
79-6 Suppresses Human DLBCL Xenografts in Mice
In order to evaluate the antilymphoma activity of 79-6, we per-
formed a preclinical study in which two BCL6-dependent DLBCL
cell lines (OCI-Ly7 and SU-DHL6) were each injected into ten
SCID mice and allowed to form tumors. Once palpable tumors
were detected, pairs of mice were randomized to receive either
50 mg/kg 79-6 (n = 5) per day or vehicle (10% DMSO) (n = 5).
In addition, one BCL6-independent cell line (Toledo) was also
implanted in SCID mice (n = 10) and treated in a similar way asCancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc. 405
Figure 7. Compound 79-6 Effectively Distributes to Lymphomas after Parenteral Administration and Suppresses DLBCL Growth In Vivo
(A) The serum (blue curve) and tumor (red curve, inset) concentrations of 79-6 were determined after the intraperitoneal administration of 50 mg/kg to mice
carrying OCI-Ly7 xenografts. Serum and tumors were harvested at several time points (x axis) and the concentration of 79-6 was determined by HPLC-MS/
MS and compared to control (time 0).
(B) Tumorgrowthplots inSU-DHL6,OCI-Ly7andToledo (asnegativecontrol) xenograftedmice treatedwithvehicle (greencircles)or 79-650mg/kg/day (redcircles)
for 10 consecutive days. The y axis represents the percentage of tumor volume (in mm3) compared with day 1 of treatment and x axis represents treatment day.
(C) Serum levels of human b2-microglobulin at day 10 in vehicle (green bars) and 79-6 (red bars) treated SU-DHL6, OCI-Ly7 and Toledo mice.
(D) Representative images from SU-DHL6, OCI-Ly7, and Toledo mice tumors after treatment with vehicle or 79-6 and assayed for apoptosis by TUNEL. Scale
bars represent 125 mm and 50 mm in main images and insets respectively. Error bars represent the SEM for replicates. See also Figure S7 and Table S4.
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Figure 8. Compound 79-6 Inhibits the
Growth of Primary Human DLBCLs
Single-cell suspensions were obtained from
lymph node biopsies of patients diagnosed with
DLBCL and were treated with either vehicle, 79-6
125 mM (black bars), or 79-6 250 mM (gray bars).
The y axis represents the percent of viable cells
compared with vehicle, which is represented by
the line at 100%. A significant response zone is
shown as a gray shadow with 75% viability as
the upper limit. Whether BCL6 was detected by
western blotting in these samples is indicated at
the bottom of the graph by the plus and minus
signs. Error bars represent the SEM for replicates.
See also Figure S8.
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animals was markedly reduced in both BCL6-dependent cell
lines, but not in the BCL6-independent tumors (Figure 7B). The
tumors in OCI-Ly7 and SU-DHL6 mice were significantly smaller
than their respective vehicle control (p = 0.001 and p = 0.004,
respectively) (Figure 7B). The levels of serum human b2-micro-
globulin (a surrogate marker of the xenograft burden) (Cerchietti
et al., 2009) were significantly reduced by 79-6 in the xeno-
grafted mice as compared with their respective controls for the
OCI-Ly7 and SU-DHL6 xenografts (p = 0.0117 and p = 0.0004,
respectively) but not in the Toledo xenograft (p = 0.7822)
(Figure 7C). Histological examination of tumors revealed an
increased fraction of cells undergoing apoptosis in 79-6 treated
animals for the OCI-Ly7 and SU-DHL6 xenografts (p = 0.0001
and p = 0.00008, respectively) (Figure 7D). There was no differ-
ence in apoptosis between 79-6 and vehicle treatments in
Toledo xenografts (Figure 7D). Taken together, these data indi-
cate that therapeutic targeting of BCL6 with the small molecule
79-6 is an effective antilymphoma strategy in vivo.
79-6 Can Specifically Kill Primary Human DLBCL Cells
Because we intend to translate BCL6 targeted therapy to the
clinical setting, we next examined whether primary human
DLBCL cells could also be killed by 79-6. Single cell suspensions
were generated from 25 confirmed DLBCL lymph node biopsy
specimens and exposed to 125 and 250 mM 79-6 or control
(DMSO) for 48 hr. A total of 21 of 25 control specimens main-
tained an acceptable viability (>80%) over the 48 hr period and
were analyzed together with the treated samples by metabolic
luminescent-based labeling in triplicate. A total of 19 of 21
DLBCLs were positive for BCL6 by western blotting (Figure 8
and Figure S8). A decrease in the viability equal or greater than
25% compared with their respective controls at either dose
was considered as significant. A total of 15 of 19 BCL6-positive
cases (79%) displayed greater than 25% loss of viability in
response to 79-6 at 125 or 250 mM (Figure 8). Therefore, most
BCL6-positive human primary DLBCL samples were responsive
to 79-6. Although we cannot exclude that cellular pathways
induced by placing primary cells in culture could potentiate the
activity of the BCL6 inhibitors, the results are consistent overall
with our cell line and xenograft data and support the notion
that most BCL6-positive tumors are potential candidates for
BCL6 inhibitor therapy.DISCUSSION
Transcriptional repressors usually mediate their effects on
gene expression through recruitment of cofactors that either
enzymatically modify the chromatin structure of target genes
or serve as adaptors for such proteins (Melnick, 2005). Thus, to
therapeutically target transcriptional repressors, it is necessary
to develop drugs that can disrupt protein-protein interactions.
Such interactions have traditionally been considered difficult to
target with low-molecular-weight compounds that have the
potential to become drug candidates (Juliano et al., 2001).
However, over the last decade small-molecule inhibitors have
been identified for an increasing number of protein-protein
interactions (Wells and McClendon, 2007; Zhong et al., 2007),
including ERK kinase (Hancock et al., 2005), S100B-p53
(Markowitz et al., 2004), eIF4E-eIF4G translation initiation factors
(Moerke et al., 2007), and others (Pagliaro et al., 2004). In the
present study, we have now extended this list to include small-
molecule inhibitors of transcriptional repressor protein interac-
tions. Experimental high-throughput screening (HTS) screening
efforts for drug-like compounds typically yield hit rates in the
range of 0.01 to 1% (Doman et al., 2002; Woodward et al.,
2006). Here, using CADD to identify candidate compounds
followed by extensive in vitro and in vivo functional testing, we
achieved a hit rate of approximately 10% (10 out of 100 tested),
emphasizing the utility of this combined approach in the identifi-
cation of active compounds. Alternatively, experimental HTS
approaches may be used to identify smaller, fragment-like mole-
cules (Woodward et al., 2006). This approach typically yields
higher hit rates, though the binding affinities are typically in the
millimolar range and the compounds have low specificity
(Chen and Shoichet, 2009). The advantage of fragment-based
screening is the ability to chemically link different candidate
fragments together, yielding higher-affinity compounds with
greater specificity; however, it is heavily reliant on chemical
synthesis. We chose to avoid this issue in our study by searching
in silico chemical databases of commercially available drug-like
compounds.
Our compound screening strategy was based on the 3D
structures of BCL6BTB corepressor BBD peptide complexes.
Although the 17 residue BBD peptides interact over a large
and mostly flat 1080 A˚2 surface of the BCL6BTB lateral groove
(Ahmad et al., 2003; Ghetu et al., 2008), a deeper pocketCancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc. 407
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complexes and we targeted this site for our rational design
efforts (Ahmad et al., 2003; Ghetu et al., 2008). The 79 series
was selected as a class of possible inhibitors due to their drug
like characteristics and because it contained several active
analogs. Although the in vitro IC50 of these compounds for
in vitro blockade of SMRT peptide association was in the micro-
molar range, and likewise, micromolar concentrations were
required to elicit the observed biological effects, our extensive
pharmacodynamic studies suggest that the compounds are
effective and specific inhibitors of BCL6. Most importantly, the
fact that 79-6 disrupts the ability of BCL6 to recruit N-CoR and
SMRT to a BCL6 target gene promoter demonstrates that this
drug achieves its proposed mechanism of action in living cells.
Collectively, these data support the conclusion that most of
the observed activity of 79-6 is due to its inhibition of BCL6.
Specifically, the following observations were made: (1) 79-6
concentrates within cells to levels greater than its IC50 for
BCL6 inhibition, a feature that it shares with recombinant BCL6
peptide inhibitors, (2) 79-6 does not inhibit other BTB transcrip-
tional repressors, (3) 79-6 disrupts endogenous BCL6 repression
complexes at a BCL6 target gene promoter, (4) 79-6 specifically
reactivates critical BCL6 target genes only in BCL6-dependent
DLBCL cells, a function that has been previously shown to be
required for BCL6 blockade to kill lymphoma cells (Cerchietti
et al., 2008; Cerchietti et al., 2009), (5) 79-6 readily kills BCL6-
dependent DLBCL cells but has almost no effect on BCL6 inde-
pendent cells, a feature that implicates BCL6 as the critical
target, (6) 79-6 analogs with weaker anti-BCL6 effects are also
less potent in killing BCL6-dependent DLBCL cells, (7) 79-6
was nontoxic to other cell types, (8) no gain-of-function activities
were observed with 79-6 versus BCL6 peptide inhibitors, and (9)
79-6 only suppressed BCL6-dependent DLBCLs in vivo, but did
not affect BCL6-independent tumors, indicating that its anti-
tumor effect is B cell autonomous.
The ability of a molecule such as 79-6 to mediate its functions
within cells is dependent, among other factors, on the cellular
context, such as the existing levels of BCL6 and corepressors
and the capacity of other protein partners of BCOR, SMRT,
and N-CoR to sequester them away from BCL6 once displaced
by 79-6. It may also not be necessary for the inhibitor to totally
block all BCL6-corepressor interactions to exert a biological
response, but rather the inhibitor may only have to shift the equi-
librium of the BCL-corepressor interactions by a relatively small
amount to achieve the desired biological and, possibly, thera-
peutic outcome. In addition, because the effect of 79-6 is to
re-express silenced target genes of BCL6, the compound does
not need to be present at all times for its effects to be evident.
For example, we showed that 79-6 induces the expression of
the critical checkpoint target genes of BCL6 atr and tp53.
Once expressed, these proteins are able to trigger their down-
stream cell death and antiproliferative pathways regardless of
whether 79-6 is still bound to BCL6.
It is also worth noting that BCL6 mediates several different
biological effects in lymphoma cells, and these appear to be
dependent on different sets of BCL6 corepressors. Specifically,
the effect of BCL6 on survival is dependent on corepressor
binding through the BTB lateral groove (at least in part due
to BCL6 repression of atr and tp53) (Cerchietti et al., 2008;408 Cancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc.Cerchietti et al., 2009; Polo et al., 2004; Ranuncolo et al.,
2007), whereas its effects on B cell differentiation are dependent
on MTA3/NuRD binding to the BCL6 middle domain (Fujita et al.,
2004; Parekh et al., 2007), and negative autoregulation is depen-
dent on recruitment of CtBP to the N-terminal half of BCL6
(Mendez et al., 2008). In accordance with its lateral groove-
specific actions, 79-6 did not affect differentiation or BCL6 nega-
tive autoregulation (data not shown). BCL6 knockout mice
develop a severe and usually fatal inflammatory syndrome due
to loss of BCL6 function in T cells and macrophages (Dent
et al., 1997; Ye et al., 1997). However, there was no evidence
of toxicity in animals treated with either lateral groove blocking
peptides (Cerchietti et al., 2009) or with 79-6. This suggests
that these biological actions of BCL6 are independent of the
lateral groove.
The five-membered ring of 79-6 contains sulfur functionality,
which is anticipated to be prone to oxidation, potentially leading
to the loss of binding to BCL6 and enhanced metabolism and/or
excretion. Current research is focused on determining the extent
of oxidation, and the replacement of the sulfur-containing
heterocycle in 79-6 with other heterocycles less prone to oxida-
tion. These modifications are also anticipated to enhance oral
availability, though it should be emphasized that the CADD
selection criteria targeted compounds with physical properties
that are predicted to have favorable bioavailability. Future efforts
will be undertaken to systematically improve the therapeutic
potential of the compounds identified in the present study with
the goal of developing BCL6 targeted therapy for DLBCL.EXPERIMENTAL PROCEDURES
Computer-Aided Drug Design
The program DOCK 4.0.1 (Ewing et al., 2001; Kuntz, 1992; Kuntz et al., 1982)
was used to screen a virtual library of approximately 1,000,000 low-molecular-
weight compounds collected fromMaybridge (80,820), Chembridge (242,869),
Chemical Diversity (333,054), Specs (207,640), MDD (22,870), Tripos (78,074),
Nanosyn (65,154), and TimeTec (15,875). Manipulation of the database was
performedwith a collection of in-house programs andwith the programMolec-
ular Operating Environment (MOE); MOE was also used for chemical similarity
calculations. Structural analysis and MD simulations were performed with the
program CHARMM (Brooks et al., 1983), with the CHARMM protein all-atom
force field (MacKerell et al., 1998). Treatment of long-range non-bond interac-
tions used default values supplied with the force field. Database screening tar-
geted a region of the lateral binding groove on BCL6 occupied by residues
S1424 and I1425 of the SMRT corepressor. Site selection was based on the
crystallographic structure of BCL-6 homodimer (RCSB Protein Data Bank
[PDB] ID 1R2B [Berman et al., 2000]), which also contains cocrystallized
SMRT peptide. Following removal of the SMRT peptide solvent, accessibilities
were determined for all BCL6 residues (chain A: F11, R13, H14, A15, D17, V18,
N21; chain B: A52, C53, S54, F89, M114, H116, V117) within 5 A˚ of SMRT resi-
dues S1424 and I1425; this procedure was performed for both SMRT binding
grooves in the homodimer. From this analysis a putative small-molecule
binding pocket was identified between BCL6 residues R13A and H116B. Initial
database screening referred to as first-step docking targeted the putative
binding site on the crystal structure. Database screening utilizes an anchor-
based ligand-docking scheme. First, each compound is divided into rigid
segments containing five or more nonhydrogen atoms, referred to as anchors.
Each anchor is then overlaid onto the sphere set in 200 different orientations
and energy minimized. For each orientation, the remainder of the compound
was iteratively built in a layer-by-layer fashion, with the layers separated by
rotatable bonds, while minimizing new torsion angles as each layer is added.
Select conformers were dynamically removed during the build-up process
based on energetic and diversity considerations. For each compound the final
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energy, calculated as the sum of electrostatic and vdW interactions, with the
binding site. Compounds were ranked according to their N normalized vdW
attractive component (i.e., EvdWa/N), where N is the number of heavy atoms
in the ligand, in order to account for the contribution of ligand molecular size
to the energy score (Pan et al., 2003). The top 50,000 compounds based on
this ranking scheme were selected for use in subsequent steps. Second-
step screening included simultaneous energy minimization of the anchor frag-
ment during iterative build-up of each ligand. In addition, each anchor was
placed into the sphere set in 500 different orientations and up to five inner
layers were optimized during the build-up process. The 50,000 compounds
selected from first-step screening were independently docked against three
BCL6 conformations: the crystal, 8950, and 9150 conformations, correspond-
ing to MD snapshots 0000 ps, 8950 ps, and 9150 ps, respectively. For each
compound, the most favorable total interaction energy from the three indi-
vidual dock runs was used for compound ranking. Final ranking was based
on the N2/5-normalized total interaction energy (i.e., Etot/N
2/5) from which the
top 1000 compounds were selected. Final selection of compounds for biolog-
ical assays was based on their chemical diversity, solubility, and potential as
drug leads. Molecular diversity was calculated by building a chemical finger-
print describing the functional groups and configurations. The 1000 top-
scoring compounds obtained in second-step screening were combined into
clusters of chemically similar compounds with the clustering tool in MOE.
Chemical fingerprints were generated with MACCS Structural Keys and clus-
tered with Tanimoto coefficient metric (Butina, 1999; Godden et al., 2005). A
final set of 199 diverse compounds was selected for biological assays. This
similarity searching procedure was also applied to active compounds 28,
33, 72, 79, 43, 44, 49, 53, and 55 for the entire chemical database to identify
chemically similar analogs of each compound.
X-ray Crystallography
Crystals of the BCL6 BTB domain were obtained by the hanging drop vapor
diffusion method by mixing 1 ml 9.5 mg/ml BCL6BTB in 20 mM Tris (pH 8.3),
450 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP) with 1 ml reservoir
solution (180 mM sodium acetate, 190 mM sodium formate, 10% glycerol,
50 mM NaCl, and 10 mM N-[4-bromophenylsulfonyl]acetamide) and equili-
brating with 500 ml reservoir solution. Crystals formed in space group C2
with unit cell dimensions a = 101.71 A˚, b= 38.61 A˚, c = 78.82, b = 114.7,
with one BCL6BTB dimer (two chains) per asymmetric unit, resulting in a solvent
content of 54%. Crystals were soaked overnight in a 1:1 mixture of protein
buffer and reservoir solution containing saturating amounts of 79-6 (2.5 mM).
Crystals were next stepped through artificial mother liquor solutions containing
5%, 15%, and 25% ethylene glycol and flash frozen in liquid nitrogen. Diffrac-
tion images were collected at beam line 19-ID at the Structural Biology Center,
Advanced Photon Source (Argonne National Laboratory), and were processed
and scaled with the HKL program suite (Minor et al., 2006). Molecular replace-
ment was performed with Phaser (Mccoy et al., 2007) with a BCL6BTB dimer
from PDB ID 1R28 as the starting model. Initial model refinement was done
with CNS (Brunger et al., 1998) with protein atoms only. Waters were subse-
quently addedwith Coot (Emsley andCowtan, 2004), followed bymore rounds
of refinement. Once this model converged, 79-6 was built into the electron
density followed by further refinement with REFMAC (Murshudov et al.,
1997). Three crystallographically unique molecules of 79-6 were found in the
electron density maps. 79-6 was found in both of the lateral groove pockets
of the BTB dimer, as described in the main text. A third molecule was found
associated with the BTB strand b3 at a crystal lattice contact site, but this
binding site does not exist in the absence of the crystal lattice, and would
not occur in solution. This is confirmed by the fact that we did not see any
resonance shifts in this region in the 79-6 NMR titrations. Final refinement
statistics are given in the Table S3. In a parallel experiment, a structure was
determined for the BCL6BTB crystal form reported here without prior soaking
in compound 79-6, and in this case, only water molecules were located in
the lateral groove. Protein structure images were produced with PyMOL
(DeLano, 2002).
Mouse Xenograft Studies
All procedures involving animals followed US NIH protocols and were
approved by the Animal Institute Committee of the Albert Einstein College ofMedicine and/or the Weill Cornell Medical College of Cornell University. Six-
to eight-week-old male SCID mice were purchased from the National Cancer
Institute (NCI, Bethesda, MD) and housed in a clean environment. Mice were
subcutaneously injected with low-passage 107 human SU-DHL6, OCI-Ly7 or
Toledo cells. Tumor volume was monitored every other day with electronic
digital calipers (Fisher Scientific) in two dimensions. Tumor volume was calcu-
lated with the formula: tumor volume (mm3) = (smallest diameter2 3 largest
diameter) / 2. When tumors reached a palpable size (approximately 75 to
100 mm3), the mice were randomized assigned to different treatment arms.
Drugs were stored in a UV light-protected vacuum desiccator at room
temperature until used and were immediately reconstituted in DMSO and
administered by i.p. injection. Mice were weighed every other day. All mice
were euthanized by cervical dislocation under anesthesia when one of each
pair reached the maximal tumor mass permitted by our protocol. At the
moment of euthanasia, blood was collected (StatSampler, Iris, Westwood,
MA) and tumors and other tissues were harvested and weighed.
Compounds
All compounds were acquired from ChemBridge (San Diego, CA) or ChemDiv
(San Diego, CA). The minimum purity of all compounds is 90%, with 60% of
compounds being > 95% pure. Compound identity was confirmed through
mass spectrometry (ThermoFinnegan LCQ). Compound 79-6 was synthe-
sized, purified and identity verified by ChemDiv Inc. The purity and identity
were verified by mass spectrometry, 1H NMR, elemental analysis, and LC/
MS. LC was performed on a SpeedROD Rp-18e 50 3 4.6 mm column at
a flow rate of 3.75 ml/min with 0.1% FA in AcN:Water (24.5:75.5) for 2.4 min,
followed by 0.1% FA in AcN:Water (90:10) for 0.2 min and a subsequent
wash with 0.1% FA in AcN:Water (24.5:75.5). MS was performed in the APCI
negative ionization mode. Results show 100% purity by LC/MS in two runs,
and combustion analysis that satisfied the ± 0.4% criteria.
Reporter Assays
For functional screening of small molecules we transfected 293T cells in a
10 cm plate using Superfect (QIAGEN, Valencia, CA) or Lipofectamine 2000
(Invitrogen) with a luciferase reporter vector containing five binding sites for
the yeast GAL4 DNA binding domain and a thymidine kinase (TK) promoter,
(GAL4)5TK-Luc (Polo et al., 2004) and an internal control TK-renilla reporter
vector, pRL-TK (Promega) at a 10:1 ratio. Cells were also transfected with
400–500 ng of a plasmid expressing the GAL4 DNA binding domain (DBD)
alone (pBXG1) or GAL4-DBD fused to the BCL6BTB. Alternatively, cells were
transfected with 1320 ng of plasmid containing the Kaiso-BTB domain fused
to GAL4-DBD, 500 ng HIC-BTB-GAL4-DBD (Polo et al., 2004), 500 ng PLZF-
BTB-GAL4-DBD (Polo et al., 2004), or 500–1320 ng GAL4-DBD alone.
Twenty-four hours after transfection cells were harvested and redistributed
to 24- or 96-well plates at a density of 400,000 or 20,000 cells per well, respec-
tively, after which cells were treated in quadruplicate with 50 or 100 mM
concentrations of different compounds or DMSO for 24 or 48 hr. Cell lysates
were examined for the abundance of firefly luciferase relative to renilla lucif-
erase (in counts per second) with the Dual-Luciferase Reporter Assay kit
(Promega, Madison, WI) and a Synergy4 plate reader (BioTek Instruments,
Winooski, VT). The repressor activity of each BTB domain was calculated as
the relative fold change in repression compared with the GAL4 DBD plasmid
control under the same treatment conditions.
Growth-Inhibition Determination
DLBCL cell lines were grown at respective concentrations sufficient to keep
untreated cells in exponential growth over the 48 hr drug exposure time. Cell
viability was determined with a luminescent ATP quantization method (Cell-
Titer-Glo, Promega), Trypan blue dye-exclusion (Sigma) and the EB/OG
method (Easycount, Immunicon). Luminescence was determined with the
Synergy4 microplate reader (BioTek). Luminescence was determined for three
replicates per treatment condition or controls. Standard curves were obtained
for each individual cell line by plotting the cell number (determined by the EB/
OG method in agreement with Trypan blue) against luminescence values. The
number of viable cells was calculated with the linear least-squares regression
of the standard curve and cell viability in drug-treated cells was normalized
to their respective controls (fractional viability). Experiments were carried out
in triplicates. For calculation purposes the drug effect was calculated asCancer Cell 17, 400–411, April 13, 2010 ª2010 Elsevier Inc. 409
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UK) to plot dose-effect curves and determine the drug concentration that
inhibits the growth of cell lines by 50% compared with control (GI50). Data
are presented as dose-effect curves and mean of GI50.
Primary Cells
Patient deidentified tissues were obtained in accordance with the guidelines
and approval of the Weill Cornell Medical College Review Board. We obtained
single cells suspensions from lymph node biopsies by physical disruption of
tissues followed by cell density gradient separation (Fico/Lite LymphoH,
Atlanta Biologicals, Lawrenceville, Georgia). Cell number and viability were
determined by an EB/AO-based method (Easycount) and cells were cultivated
in medium containing 80% RPMI and 20% human serum supplemented with
antibiotics, L-glutamine and HEPES for 48 hr. Primary cells were exposed to
125 and 250 mM 79-6 or control (DMSO) in triplicates. After 48 hr of exposure,
viability was determined with an ATP-based luminescent method (CellTiter-
Glo) and EB/AO. Specimens with 20% or higher loss of viability in the controls
were discarded. Lysates from these tissues were prepared with 50 mM Tris
(pH 7.4), 150 mM NaCl, and 1% NP-40 lysis buffer. Protein concentrations
were determined with the BCA kit (Pierce, Rockford, Illinois). Fifty mg of protein
lysates were resolved by SDS-PAGE, transferred to nitrocellulose membrane,
and probed with rabbit anti-BCL6 N3 (Santa Cruz) and rabbit anti-Actin (Santa
Cruz). Membranes were then incubated with a peroxidase-conjugated corre-
spondent secondary antibody.Detectionwasperformedwith anECLdetection
system (Vector, Burlingame, CA) according to the manufacturer’s instructions.
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